Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023

Federico Martinón-Torres; Susana Mirás-Carballal; Carmen Durán-Parrondo

doi:10.2807/1560-7917.ES.2023.28.49.2300606

Rapid communication Open Access

Like 0

Download

Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023
Federico Martinón-Torres^1,2,3,4 , Susana Mirás-Carballal⁵ , Carmen Durán-Parrondo⁵
View Affiliations Hide Affiliations

Affiliations: ¹ Genetics, Vaccines and Paediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain ² Translational Paediatrics and Infectious Diseases, Hospital Clínico Universitario and University of Santiago de Compostela (USC), Santiago de Compostela, Spain ³ World Health Organization Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain ⁴ Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain ⁵ Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain

Correspondence:
Federico Martinón-Torres
federico.martinon.torres sergas.es
View Citation Hide Citation

Citation style for this article: Martinón-Torres Federico, Mirás-Carballal Susana, Durán-Parrondo Carmen. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill. 2023;28(49):pii=2300606. https://doi.org/10.2807/1560-7917.ES.2023.28.49.2300606 Received: 04 Nov 2023; Accepted: 29 Nov 2023

Abstract

A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individualised appointments and educational activities, nirsevimab uptake was 97.5% in the high-risk group, 81.4% in the catch-up group and 92.6% in infants born during the campaign. This successful implementation strategy can serve as a model and may inform other countries’ programmatic deliberations.

This work is licensed under a Creative Commons Attribution 4.0 International License.

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.49.2300606

2023-12-07

2024-12-12

Click here for cited by

http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.49.2300606

Full text loading...

/deliver/fulltext/eurosurveillance/28/49/eurosurv-28-49-3.html?itemId=/content/10.2807/1560-7917.ES.2023.28.49.2300606&mimeType=html&fmt=ahah

References

Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341-53. https://doi.org/10.1016/S2213-2600(22)00414-3 PMID: 36372082
Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023;21(11):734-49. https://doi.org/10.1038/s41579-023-00919-w PMID: 37438492
Martinón-Torres F, Navarro-Alonso JA, Garcés-Sánchez M, Soriano-Arandes A. The path towards effective respiratory syncytial virus immunization policies: recommended actions. Arch Bronconeumol. 2023;59(9):581-8. https://doi.org/10.1016/j.arbres.2023.06.006 PMID: 37414639
Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015-2018. BMC Infect Dis. 2023;23(1):385. https://doi.org/10.1186/s12879-023-08358-x PMID: 37291530
Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022;22(1):759. https://doi.org/10.1186/s12879-022-07745-0 PMID: 36175846
Mao Z, Li X, Dacosta-Urbieta A, Billard MN, Wildenbeest J, Korsten K, et al. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe. Vaccine. 2023;41(16):2707-15. https://doi.org/10.1016/j.vaccine.2023.03.024 PMID: 36941154
McGinley JP, Lin GL, Öner D, Golubchik T, O’Connor D, Snape MD, et al. Clinical and viral factors associated with disease severity and subsequent wheezing in infants with respiratory syncytial virus infection. J Infect Dis. 2022;226(Suppl 1):S45-54. https://doi.org/10.1093/infdis/jiac163 PMID: 35902389
Johannesen CK, van Wijhe M, Tong S, Fernández LV, Heikkinen T, van Boven M, et al. Age-specific estimates of respiratory syncytial virus-associated hospitalizations in 6 European countries: a time series analysis. J Infect Dis. 2022;226(Suppl 1):S29-37. https://doi.org/10.1093/infdis/jiac150 PMID: 35748871
Ares-Gomez S, Mallah N, Pardo-Seco J, Nartallo-Penas V, Mirás-Carballal S, Rodriguez-Tenreiro-Sánchez C, et al. Improving influenza vaccine acceptance in children leveraging on COVID-19 vaccination lessons. Arch Bronconeumol. 2023;59(8):531-3. https://doi.org/10.1016/j.arbres.2023.03.011 PMID: 37003883
Galician RSV immunoprophylaxis campaign. Respira tranquilo. [Breathe easy]. Santiago de Compostela: Council of Galicia. [Accessed: 4 Nov 2023]. Available from: https://www.sergas.es/Saude-publica/INMUNIZACION-FRONTE-AO-VIRUS-RESPIRATORIO-SINCITIAL

Submit comment

Comment moderation successfully completed

Submit your article here

Submit an Article

Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023

Abstract

Click here for cited by